Cara Therapeutics (CARA)
(Real Time Quote from BATS)
$0.29 USD
-0.01 (-3.65%)
Updated Sep 24, 2024 11:56 AM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Cara Therapeutics, Inc. [CARA]
Reports for Purchase
Showing records 1 - 20 ( 58 total )
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Oral DFK Final Shot on Goal Missed; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Oral DFK NP Pivotal De-Risking Catalyst by End June; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Stock Undervaluing Oral DFK in NP, With Key Data by Early-3Q; Raise Target to a Risk-Discounted $3.60; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Oral DFK Misses High Bar in AD-Pruritus; Now Look to 2H24 Data in Other Indications; Lower to $2.50, But Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Big Disconnect Between Stock and Oral DFK Potential; Crucial Atopic Derm Data in December; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Shifting Gears: Now an Oral DFK Story; Street Sleeping on Important Atopic Derm Data by December; New $7 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IV Korsuva Slower Acceleration Than We?d Modeled; See Similar Peak Opportunity But Moderated Ramp; PT Lower to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Big 4Q Inventory Drag Spooks Street; We Lower, But Think Reaction to Temporarily Depressed Ramp is Overdone; PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moderating Initial IV Korsuva Patient Ramp to Account for Inventory Dynamics; Strongly Reiterate Buy But Lower PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Korsuva Injection Volume Ramp Should Dispel Launch Doubts and Inject Life into the Stock; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Korsuva Profitability Even Higher Than We Thought; Makes Up for Later to Ramp Big Dialysis Center Orders; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: IV Korsuva Partner Launch Underway and Underappreciated; Major Valuation Disconnect, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IV Korsuva Launch Weeks Away; Oral Korsuva Phase 3s Take Shape; Moderating Target on Long-Term Pricing
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Stock Undervalues Imminent IV Korsuva Launch, In Our View; Oral Korsuva Phase 3 Plans Taking Shape; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IV Korsuva Approved; 1Q22 Launch; Raise PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: IV Korsuva PDUFA 2 Weeks Away; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Undervalued Ahead of IV Korsuva August PDUFA; Potential Less-Risky Pathway in Pre-dialysis CKD-aP
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Nothing Changes in Our Valuation; Atopic Dermatitis Wasn''t In Our Model; Reiterate $33 Target Ahead of IV Korsuva PDUFA
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Cara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IV Korsuva Gets Priority Review; Imminent Oral Korsuva AD Data Entirely Potential Upside to Our Valuation
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O